What are the latest funding trends in Longevity Biotech?

All funding deals in the Longevity Biotech Market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the Longevity Biotech Market.

Is longevity biotech funding really booming right now?

Longevity biotech funding is clearly having a stronger year, although the biggest change is the number of companies getting financed rather than a broad jump in round sizes.

We counted 43 financings in the current YTD period, compared with 30 over the same stretch last year and 27 two years ago. The number of funded companies rose from 29 to 39 in one year. That gives us much more confidence in the acceleration than the headline capital figure alone would.

Capital has moved much faster. Disclosed funding reached $1.914 billion, versus $912.8 million last year and $614.5 million two years ago. Yet the median round slipped from $10.5 million to $8 million.

So the market is busier today, but the huge increase in dollars is concentrated much higher up the funding ladder.

Metric	Current YTD	Previous YTD	Two years ago	Change vs previous YTD
Financings	43	30	27	+43.3%
Funded companies	39	29	27	+34.5%
Disclosed capital	$1.914B	$912.8M	$614.5M	+109.7%
Median disclosed round	$8.0M	$10.5M	$8.5M	-23.8%
Average disclosed round	$51.7M	$32.6M	$22.8M	+58.7%
Largest round	$700M	$260M	$170M	+169.2%
Companies raising more than once	4	1	0	+3 companies

Would longevity biotech funding still look strong without the giant rounds?

Longevity biotech funding still looks better without the giant rounds, but the supposed funding boom becomes much smaller.

Once we remove financings above $50 million, current funding falls to $329 million. That is only 19% above last year's comparable $276.8 million and almost identical to the $325.5 million recorded two years ago.

The larger rounds therefore explain most of the dollar acceleration. Neko Health raised $700 million, NewLimit raised $435 million and Cognito Therapeutics raised $105 million. Those three deals alone absorb close to two thirds of disclosed funding.

Looking above $100 million gives us another useful check. Capital after removing those rounds comes to $674 million, still 67% ahead of last year. There is real improvement below the absolute top of the market, especially among rounds in the $50 million to $100 million range, but ordinary-sized financing has changed far less than the $1.9 billion headline suggests.

Are more longevity startups actually getting funded today?

Yes. More longevity startups are getting financed now, and this is one of the clearest improvements in the market.

Funded-company count increased by roughly a third in one year, while financings rose by more than 40%. Repeat fundraising contributed to the increase, but only four companies completed multiple financings during the current period.

Seed activity is especially active. We counted 25 Seed financings, nearly twice the 13 recorded in the comparable period last year. That is a meaningful increase in startup formation and early financing.

The checks at this end remain fairly modest. Seed rounds represent 58% of all deals and less than 5% of disclosed capital. More founders are getting through the first funding gate these days, even as the bulk of the money flows elsewhere.

Are normal longevity funding rounds getting bigger?

Normal longevity funding rounds are actually a little smaller right now.

The current median is $8 million, down from $10.5 million last year. Deals below $20 million make up more than half of all current financings, while the $20 million-to-$50 million segment shrank from 20% of deals to 14%.

The upper end moved in the opposite direction. Four financings above $100 million account for 70% of current capital. Last year, three such rounds represented 56%.

That gap between an $8 million median and a $51.7 million average makes the distribution unusually skewed. A founder raising a fairly standard longevity Seed or Series A is living in a very different funding market from Neko Health or NewLimit.

Round size	Current deals	Current deal share	Current capital share
Below $5M	10	23.3%	1.3%
$5M–<$20M	14	32.6%	6.4%
$20M–<$50M	6	14.0%	9.6%
$50M–<$100M	3	7.0%	12.8%
$100M+	4	9.3%	70.0%
Amount undisclosed	6	14.0%	-
All financings	43	100%	100% of disclosed capital

Why are Neko Health and NewLimit able to raise so much money now?

Neko Health and NewLimit are raising extraordinary sums because investors can now point to much more concrete operating or development progress around both companies.

Neko Health is the clearest commercial example. When the company announced its $700 million Series C, it reported more than 350,000 people registered or waiting for a scan, more than 100,000 people already scanned in Sweden and the UK, and a 75% rebooking and prepayment rate after the first appointment.

The story has moved further since the financing. Neko has now opened its first U.S. clinic in New York. More than 25,000 New Yorkers had joined the local waitlist before opening, according to the company's September launch announcement. Neko's latest Year Three report also covers more than 80,000 members and 92,000 scans, giving investors a much larger real-world operating dataset than the company had a few years ago.

NewLimit's $435 million Series C comes from a very different part of longevity. The company says its first reprogramming medicine is heading toward human trials next year. Its latest technical update also reported more than 120-fold manufacturing scale-up for its lead asset, progress toward pivotal nonclinical studies and new functional results in old endothelial cells.

Those are the kinds of milestones that can support unusually large financing rounds. Investors have much more to underwrite than a scientific thesis alone.

Is longevity biotech becoming a later-stage market?

Longevity biotech still produces lots of early-stage deals, while later-stage companies now take an overwhelming share of the money.

Seed and Series A together account for roughly 70% of current financings, almost unchanged from last year. Anyone looking only at deal count would struggle to argue that early-stage longevity has disappeared.

Capital allocation tells a much stronger story. Series C alone absorbed $1.34 billion, or 70% of all disclosed funding, through only four financings. Later-stage rounds collectively captured more than four fifths of disclosed dollars.

Neko Health, NewLimit and other mature companies have changed the shape of the market. Investors still finance a large pipeline of young startups, then reserve truly large checks for a small group that has reached a much more advanced point.

Stage	Current deals	Current capital	Previous-period deals	Previous-period capital
Seed	25	$92.1M	13	$71.0M
Series A	5	$182.9M	8	$162.3M
Series B	3	$135.5M	6	$626.0M
Series C	4	$1.340B	0	-
Series D+	2	$116.5M	0	-
Unknown	4	$47.0M	3	$53.5M
All stages	43	$1.914B	30	$912.8M

Can a new longevity startup still raise money?

A new longevity startup can still raise money today, but first checks have become noticeably smaller.

We found 14 first financings in the current period, compared with 12 last year and only five two years ago. There is little evidence here that new startups are being shut out altogether.

Known capital going into those first financings fell sharply, however, from about $151 million to $52 million. Their median round dropped from $10 million to $4.8 million.

Follow-on financing went the other way. We counted 28 follow-ons versus 18 last year, with known capital rising from about $762 million to $1.85 billion. The median follow-on remained at $20 million.

The split is becoming quite stark: longevity investors are still willing to fund new experiments, while companies that already have financing history and stronger evidence can access a completely different pool of capital.

Because financing status comes from a lightweight review of publicly available financing histories, we use this comparison directionally rather than claiming a perfect reconstruction of every company's lifetime funding record.

Are longevity investors becoming more selective?

Longevity investors look more selective about check size than about the number of startups they will back.

These days, more companies are getting funded, Seed activity is high and the lead-investor pool has widened considerably. At the same time, the first check tends to be smaller and the largest checks are clustering around a few advanced companies.

The top five rounds capture 74.5% of all disclosed capital. Two years ago, the top five represented 62.2%. The market is getting more polarized.

For founders, the practical message is pretty simple. Getting financed still looks possible across a broad part of longevity. Getting financed at very large scale increasingly requires convincing investors that a company has moved beyond the early scientific or product-risk phase.

Which part of longevity biotech is attracting the most investor attention?

Longevity Therapeutics currently has the strongest funding momentum because it is gaining both deals and dollars.

Therapeutics represented 41.9% of financings this year, up from 33.3% last year. Its capital share increased from 41.1% to 51.3%. That is a cleaner gain than we see anywhere else in the market.

Preventive Health Platforms also increased their share of activity to 41.9%, although their share of capital slipped. Neko Health makes that category look much richer than the rest of its companies.

Healthy Aging Clinics clearly cooled. Their deal share fell from 16.7% to 4.7%, while capital share dropped from 7.2% to just 0.5%.

The two-year comparison is useful here too. Longevity Therapeutics already represented more than half of deals two years ago, so the current strength looks partly like a recovery from last year's weaker period. Preventive platforms show a more obvious multi-year expansion in financing activity.

Longevity category	Current deal share	Previous YTD	Two years ago	Current capital share
Longevity Therapeutics	41.9%	33.3%	51.9%	51.3%
Preventive Health Platforms	41.9%	33.3%	11.1%	43.9%
Healthy Aging Clinics	4.7%	16.7%	11.1%	0.5%
Consumer Longevity Brands	4.7%	10.0%	7.4%	3.0%
Diagnostics/Biomarkers	4.7%	3.3%	3.7%	0.5%
Aging Research Platforms	2.3%	3.3%	14.8%	0.9%
All categories	100%	100%	100%	100%

Is preventive health really taking off in the longevity market?

Preventive health is taking off by deal activity, and Neko Health is turning that broader trend into a huge capital story.

We counted 18 Preventive Health Platform financings today, compared with 10 last year and only three two years ago. The multi-year direction is hard to miss.

Neko still creates a major distortion in the dollar total. Its $700 million Series C represents around 83% of all current capital in the category.

Other companies show what the underlying expansion looks like at a more normal scale. Everlab raised AU$65 million in a Series A to expand its integrated preventive-care platform. The company said the platform was already connecting more than 1,850 health-provider locations, over 180 clinicians and more than 30 wearable devices, while processing more than 200,000 health reports per month. Everlab has also expanded into New Zealand and plans to use the new capital for a wider global rollout.

Neko has since opened in New York, while its website now lists planned locations in additional U.S. cities. The current wave has more behind it than funding announcements alone: several preventive-health companies are actively moving into new markets.

Why is longevity therapeutics getting bigger checks?

Longevity therapeutics is getting bigger checks because several companies are moving from discovery work toward clinical, regulatory or late-development milestones.

NewLimit is the obvious example. Its latest updates describe manufacturing scale-up and final preclinical work ahead of planned first-in-human studies. That changes the type of risk investors are financing.

Loyal provides another version of the same story. The company raised $100 million after completing two of the three major technical requirements it says are needed for expanded conditional approval of LOY-002, its longevity drug for senior dogs. Its large STAY study has enrolled more than 1,300 dogs across more than 70 veterinary clinics.

The FDA's own guidance makes the significance of that pathway clearer. Expanded conditional approval can allow qualifying animal drugs to reach the market after safety and a reasonable expectation of effectiveness have been established, while the company continues gathering evidence needed for full approval.

Cognito Therapeutics adds another $105 million Series C to the current therapeutic pool. The company's financing is intended to advance Spectris in Alzheimer's disease, showing how our longevity dataset also captures companies working on specific age-related diseases rather than only companies explicitly marketing an anti-aging treatment.

There is a broader institutional backdrop too. The National Institute on Aging has been actively asking researchers and companies about the development pipeline and barriers facing disease-modifying drugs that target mechanisms linked to aging-related conditions. That does not explain private financing by itself, but it shows how translational geroscience is becoming a more concrete drug-development field.

Is longevity funding becoming less dependent on North America?

Longevity deal activity has become much more geographically spread out, even though the biggest pools of capital are still highly concentrated.

North America now represents 39.5% of financings, down sharply from 73.3% last year. Europe rose from 13.3% to 27.9%, Asia-Pacific from 13.3% to 23.3%, and the Middle East went from no deals to four.

Asia-Pacific is probably the cleaner expansion story. Ten financings came from the region, more than double last year's count, but they represented only 4.1% of disclosed capital. That suggests a widening startup base rather than one huge transaction manufacturing the change.

Europe needs more caution. European companies captured 45.5% of current capital, yet Neko Health supplies roughly four fifths of that amount.

Global participation is broadening much faster by company count than by capital. For now, large-check funding remains far more geographically uneven than startup activity.

Region	Current deals	Current deal share	Previous deal share	Current capital share
North America	17	39.5%	73.3%	49.8%
Europe	12	27.9%	13.3%	45.5%
Asia-Pacific	10	23.3%	13.3%	4.1%
Middle East	4	9.3%	0%	0.6%
North America + Europe	29	67.4%	86.6%	95.3%
Asia-Pacific + Middle East	14	32.6%	13.3%	4.7%
All regions	43	100%	100%	100%

Are more investors willing to lead longevity rounds now?

Yes. Longevity has a much wider lead-investor pool today, which may be a better sign of market depth than the record capital total.

We identified 41 unique disclosed lead or co-lead investors in the current period, up from 26 last year and 22 two years ago. Deals with a disclosed lead also increased from 23 to 31.

The striking part is how little repetition we found. RTP Global is the only disclosed lead appearing twice in the current period. That leaves the market spread across a large number of different investors rather than controlled by a handful of recurring longevity specialists.

We would avoid reading too much into individual firms disappearing from one year's list. Thirty to forty deals are not enough to conclude that an investor has exited a sector simply because it has not led another round yet.

The broader shift is harder to dismiss: more institutions are now willing to take responsibility for pricing and leading longevity financings.

Are pharmaceutical and other strategic investors moving into longevity?

Strategic investors are showing up a little more often in longevity, with most of the current activity concentrated in therapeutics.

We found strategic investors in six current financings, compared with three last year. Four of those six deals involved Longevity Therapeutics.

NewLimit is the transaction that dominates the money. Eli Lilly Ventures participated in the company's $435 million Series C, and that one financing represents roughly 86% of current disclosed capital attached to strategic-investor deals.

That makes the direction interesting while still leaving us with a small sample. Six deals are enough to notice, especially when strategic participation clusters around therapeutic development, but they do not support a sweeping claim that pharmaceutical companies are flooding into longevity.

For now, strategic capital looks like a selective bet on a few programs getting closer to actual drug development.

Are investors funding younger longevity companies or older winners?

Longevity investors are doing both: more young companies are entering the funnel, while older companies take most of the serious money.

The median company age at financing is about three years today, compared with 3.5 years last year and five years two years ago. Seed companies have a median age of roughly two years.

Further up the funding ladder, the companies are much older. Series B recipients have a median age of nine years, Series C companies 7.5 years and Series D+ companies 13 years.

This helps make sense of the current funding market. The startup population is becoming younger because there are many more Seed deals, while the capital-weighted market is being shaped by companies that have already spent years building products, generating evidence or advancing development programs.

That barbell is more useful for founders than the headline funding total: new longevity companies are getting shots, but large-scale financing usually comes much later.

Has longevity funding already passed last year's full-year level?

Current longevity funding has already passed the entire previous year on both deal count and disclosed capital.

The current period has produced 43 financings, compared with 42 across the whole previous year. Disclosed current capital of $1.914 billion is already around 30% higher than the previous full-year total of $1.473 billion.

The comparison becomes much tighter once large rounds are stripped out. Current capital excluding financings above $50 million has reached about 89% of the previous full-year total on that same basis.

This leaves plenty of room for the year to finish exceptionally strongly, especially on transaction count. We would be much more cautious about treating the current capital pace as a new normal because a handful of very large transactions can shift the annual total by hundreds of millions of dollars.

So what is actually changing in longevity biotech funding?

Longevity biotech is expanding at the bottom and concentrating at the top, and that split is the defining change in funding right now.

More companies are raising money, Seed activity has climbed sharply and lead-investor participation is much broader. Those findings make the current improvement more convincing than a simple megaround story.

The typical financing has not enjoyed the same boom. Median round size is lower, first financings are smaller, and removing deals above $50 million reduces the year-on-year capital increase to less than one fifth.

The biggest change in dollars is happening among companies that can show substantially more progress. Neko Health now has more than 100,000 scans completed and has entered the U.S.; NewLimit is scaling manufacturing before planned human studies; Loyal has cleared major regulatory-development steps; Everlab is taking its preventive-health model overseas.

Longevity Therapeutics currently has the cleanest category momentum, while Preventive Health Platforms have the strongest multi-year expansion in deal activity. Healthy Aging Clinics have moved backward.

Geographically, the market is also becoming much wider. Asia-Pacific and the Middle East now account for almost a third of deals, even though they attract less than 5% of capital.

As seen above, the conclusion goes beyond the $1.914 billion headline. Longevity has more startups, more financings and more investors in the market today, while the really large checks are increasingly reserved for companies that can show clinical, regulatory or commercial progress.